Zions Bancorporation N.A. Has $158,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Zions Bancorporation N.A. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.5% in the fourth quarter, Holdings Channel reports. The firm owned 672 shares of the biopharmaceutical company’s stock after acquiring an additional 80 shares during the period. Zions Bancorporation N.A.’s holdings in Alnylam Pharmaceuticals were worth $158,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of ALNY. Mutual of America Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 26.7% during the 3rd quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 405 shares during the last quarter. Pathstone Holdings LLC increased its stake in shares of Alnylam Pharmaceuticals by 11.2% in the third quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock worth $1,719,000 after purchasing an additional 629 shares during the period. Cerity Partners LLC lifted its position in shares of Alnylam Pharmaceuticals by 133.6% during the 3rd quarter. Cerity Partners LLC now owns 13,019 shares of the biopharmaceutical company’s stock worth $3,581,000 after purchasing an additional 7,445 shares during the last quarter. Algert Global LLC boosted its stake in Alnylam Pharmaceuticals by 401.3% during the 3rd quarter. Algert Global LLC now owns 9,825 shares of the biopharmaceutical company’s stock valued at $2,702,000 after purchasing an additional 7,865 shares during the period. Finally, Swedbank AB grew its holdings in Alnylam Pharmaceuticals by 160.3% in the 3rd quarter. Swedbank AB now owns 53,729 shares of the biopharmaceutical company’s stock valued at $14,777,000 after buying an additional 33,090 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ALNY has been the subject of several research reports. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday, March 21st. Royal Bank of Canada increased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday, March 21st. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $312.30.

Alnylam Pharmaceuticals Trading Down 4.2 %

ALNY stock opened at $269.21 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $34.85 billion, a price-to-earnings ratio of -124.06 and a beta of 0.39. The business has a fifty day moving average price of $258.98 and a 200 day moving average price of $260.32. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.